The role of angiogenesis in the pathogenesis of psoriasis

Autoimmunity

Volumn 42, Issue 7, 2009, Pages 574-579

  Chua, Ramon Alvin ^a   Arbiser, Jack L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Autoimmune; Pathogenesis; Psoriasis; Skin

Indexed keywords

ANGIOPOIETIN 2; BEVACIZUMAB; ETRETIN; GLUCOCORTICOID; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 22; METHOTREXATE; NVP BAW2881; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CHRONIC INFLAMMATION; GENETIC ASSOCIATION; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PSORIASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; NEOVASCULARIZATION, PATHOLOGIC; PSORIASIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71049114213     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930903002461     Document Type: Review

References (67)

1. Bastard JP,Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17(1):4-12.
2. Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007;33(1-2):45-56.
3. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: A new paradigm for cutaneous inflammation. J Dermatolog Treat 2008;19(5):259-266.
4. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, Gonzalez J, Krueger JG, LowesMA. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009;129(1):79-88.
5. Elias PM, Arbiser J, Brown BE, Rossiter H, Man MQ, Cerimele F, Crumrine D, Gunathilake R, Choi EH, Uchida Y, Tschachler E, Feingold KR. Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: Implications for the pathogenesis of psoriasis. Am J Pathol 2008;173(3):689-699.
6. Stemmler S, Parwez Q, Petrasch-Parwez E, Epplen JT, Hoffjan S. Two common loss-of-function mutations within the filaggrin gene predispose for early onset of atopic dermatitis. J Invest Dermatol 2007;127(3):722-724.
7. Barker JN, Palmer CN, Zhao Y, Liao H, Hull PR, Lee SP, Allen MH, Meggitt SJ, Reynolds NJ, Trembath RC, McLean WH. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol 2007;127(3):564-567.
8. Nickoloff BJ. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: Human skin model of psoriasis. J Investig Dermatol Symp Proc 2000;5(1):67-73.
9. Sugano M, Iwasaki Y, Abe M, Maeda T, Tsuchida K, Makino N. TNF-alpha employs a protein-tyrosine phosphatase to inhibit activation of hepatocyte growth factor receptor and hepatocyte growth factor-induced endothelial cell proliferation. Mol Cell Biochem 2009;322(1-2):113-117.
10. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994;144(4):820-828.
11. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101(7):2620-2627.
12. Stenderup K, Rosada C,Worsaae A, Clausen JT, Norman DT. Interleukin-20 as a target in psoriasis treatment. Ann NYAcad Sci 2007;1110:368-381.
13. Langowski JL, Zhang X,Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M. IL-23 promotes tumour incidence and growth. Nature 2006; 442(7101):461-465.
14. Villadsen LS, Schuurman J, Beurskens F, Dam TN, gnaes- Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, Parren PW, Baadsgaard O, van de Winkel JG. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003;112(10):1571-1580.
15. Perry BN, Govindarajan B, Bhandarkar SS, Knaus UG, Valo M, Sturk C, Carrillo CO, Sohn A, Cerimele F, Dumont D, Losken A, Williams J, Brown LF, Tan X, Ioffe E, Yancopoulos GD, Arbiser JL. Pharmacologic Blockade of Angiopoietin-2 Is Efficacious against Model Hemangiomas in Mice. J Invest Dermatol 2006;126(10):2316-2322.
16. Daly C, Pasnikowski E, Burova E, Wong V, Aldrich TH, Griffiths J, Ioffe E, Daly TJ, Fandl JP, Papadopoulos N, McDonald DM, Thurston G, Yancopoulos GD, Rudge JS. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci USA 2006; 103(42):15491-15496.
17. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001;116(5):713-720.
18. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006;12(2):235-239.
19. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41(2): -1204.
20. Boehncke WH, Dressel D, Zollner TM, Kaufmann R. Pulling the trigger on psoriasis. Nature 1996;379(6568):777.
21. Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: Detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol 1999;135(5):546-552.
22. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180(3):1141-1146.
23. Rosenberger C, Solovan C, Rosenberger AD, Jinping L, Treudler R, Frei U, Eckardt KU, Brown LF. Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J Invest Dermatol 2007;127(10):2445-2452.
24. SimonettiO, Lucarini G, Goteri G, Zizzi A, Biagini G, Lo ML, Offidani A. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: Results of an immunohistochemical study. Int J Immunopathol Pharmacol 2006;19(4):751-760.
25. Henno A, Blacher S, Lambert C, Colige A, Seidel L, Noel A, Lapiere C, de la BM, Nusgens BV. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis. Br J Dermatol 2009; 160(3):581-590.
26. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141(6):1054-1060.
27. Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brunner N, Petersen LJ, Kristensen JK. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002;51(11):563-567.
28. CreamerD, Allen M, Jaggar R, Stevens R, Bicknell R, Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002;138(6):791-796.
29. Fink AM, Cauza E, Hassfeld W, Dunky A, Bayer PM, Jurecka W, Steiner A. Vascular endothelial growth factor in patients with psoriatic arthritis. Clin Exp Rheumatol 2007; 25(2):305-308.
30. Hao Q, Wang L, Tang H. Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells. Am J Physiol Cell Physiol 2009;296(4):C821-C827.
31. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates VEGF expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappa B through the CBM (Carma3/Bcl10/Matl1) complex. J Biol Chem 2009;284(10): -16042.
32. Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 2007;18(12):5014-5023.
33. Man XY, Yang XH, Cai SQ, Bu ZY, Zheng M. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: Regulated by calcium independent of VEGF. J Cell Mol Med 2008;12(2):649-660.
34. Zhang Y, Furumura M, Morita E. Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165. Growth Factors 2008;26(3):125-131.
35. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004;122(1):209-215.
36. Barile S, Medda E, Nistico L, Bordignon V, Cordiali-Fei P, Carducci M, Rainaldi A, Marinelli R, Bonifati C. Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. Exp Dermatol 2006;15(5):368-376.
37. Lee JH, Cho EY, Namkung JH, Kim E, Kim S, Shin ES, Lee JE, Yang JM. Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in Koreans. J Invest Dermatol 2008;128(6):1599-1603.
38. Shrader CD, Ressetar HG, Luo J, Cilento EV, Reilly FD. Acute stretch promotes endothelial cell proliferation in wounded healing mouse skin. ArchDermatol Res 2008;300(9):495-504.
39. Mammoto A, Mammoto T, Ingber DE. Rho signaling and mechanical control of vascular development. Curr Opin Hematol 2008;15(3):228-234.
40. Weninger W, Rendl M, Mildner M, Tschachler E. Retinoids downregulate vascular endothelial growth factor/vascular permeability factor production by normal human keratinocytes. J Invest Dermatol 1998;111(5):907-911.
41. Lee CS, Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother 2005;6(10):1725-1734. (Pubitemid 41167679)
42. Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, Smith CH, Barker JN, Detmar MJ, Brenchley PE, Griffiths CE. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006; 126(2):453-459.
43. Cordiali-Fei P, Trento E, D'Agosto G, Bordignon V, Mussi A, Ardigo M, Mastroianni A, Vento A, Solivetti F, Berardesca E, Ensoli F. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann NY Acad Sci 2007;1110:578-589.
44. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008;121(Pt20):3487-3495.
45. Akman A, Yilmaz E, Mutlu H, Ozdogan M. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol 2009;34(5):e202-204.
46. Halin C, Fahrngruber H, Meingassner JG, Bold G, Littlewood- Evans A, Stuetz A, Detmar M. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008;173(1):265-277.
47. Xia YP, Li B, Hylton D, Detmar M, Yancopoulous GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003 Jul;102(1):161-168.
48. Zheng Y, Niyonsaba F, Ushio H, Nagaoka I, Ikeda S, Okumura K, Ogawa H. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils. Br J Dermatol 2007;157(6): -11131.
49. Zughaier SM, Shafer WM, Stephens DS. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 2005;7(9):1251-1262.
50. Howell MD, Novak N, Bieber T, Pastore S, Girolomoni G, Boguniewicz M, Streib J, Wong C, Gallo RL, Leung DY. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol 2005;125(4):738-745.
51. Peric M, Koglin S, Kim SM, Morizane S, Besch R, Prinz JC, Ruzicka T, Gallo RL, Schauber J. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol 2008;181(12):8504-8512.
52. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. NEngl J Med 2002;347(15):1151-1160.
53. NogralesKE, ZabaLC,Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I, Khatcherian A, Gonzalez J, Pierson KC, White TR, Pensabene C, Coats I, Novitskaya I, LowesMA, KruegerJG.Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyteresponse pathways. Br J Dermatol 2008;159(5):1092-1102.
54. Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005;152(1):37-42.
55. Yu XJ, Li CY, Dai HY, Cai DX,Wang KY, Xu YH, Chen LM, Zhou CL. Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Exp Mol Pathol 2007;83(3):413-418.
56. Johansen C, Funding AT, Otkjaer K, Kragballe K, Jensen UB, Madsen M, Binderup L, Skak-Nielsen T, Fjording MS, Iversen L. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 2006;176(3):1431-1438.
57. Hobbs RM, Silva-Vargas V, Groves R,Watt FM. Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol 2004;123(3):503-515.
58. Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005;124(6): -11283.
59. Schmidt KN, Podda M, Packer L, Baeuerle PA. Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes. J Immunol 1996;156(11):4514-4519.
60. Schmidt KN, Amstad P, Cerutti P, Baeuerle PA. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. Chem Biol 1995;2(1):13-22.
61. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440(7086):944-948.
62. Bohne M, Struy H, Gerber A, Gollnick H. Effects of retinoids on the generation of neutrophil-derived reactive oxygen species studied by EPR spin trapping techniques. Inflamm Res 1997;46(10):423-424.
63. Zhang M, Zhu L, Feng Y, Yang Y, Liu L, Ran Y. Effects of acitretin on proliferative inhibition and RANTES production of HaCaT cells. Arch Dermatol Res 2008;300(10):575-581.
64. Caproni M, Antiga E, Melani L, Volpi W, Del BE, Fabbri P. Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in patients with psoriasis: A randomized controlled trial. J Clin Immunol 2009;29(2):210-214.
65. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008; 47(3):249-255.
66. Rezvani HR, Dedieu S, North S, Belloc F, Rossignol R, Letellier T, de VH, Taieb A, Mazurier F. Hypoxia-inducible factor-1alpha, a key factor in the keratinocyte response to UVB exposure. J Biol Chem 2007;282(22):16413-16422.
67. Maresca V, Flori E, Briganti S, Camera E, Cario-Andre M, Taieb A, Picardo M. UVA-induced modification of catalase charge properties in the epidermis is correlated with the skin phototype. J Invest Dermatol 2006;126(1):182-190.